APA (7th ed.) Citation

HK, G., S, P., AB, L., A, S., E, L., ST, L., . . . AM, S. (2021). Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neuro-oncology advances, 3(1), vdab102. https://doi.org/10.1093/noajnl/vdab102

Chicago Style (17th ed.) Citation

HK, Gan, et al. "Tumor Volumes as a Predictor of Response to the Anti-EGFR Antibody Drug Conjugate Depatuxizumab Mafadotin." Neuro-oncology Advances 3, no. 1 (2021): vdab102. https://doi.org/10.1093/noajnl/vdab102.

MLA (9th ed.) Citation

HK, Gan, et al. "Tumor Volumes as a Predictor of Response to the Anti-EGFR Antibody Drug Conjugate Depatuxizumab Mafadotin." Neuro-oncology Advances, vol. 3, no. 1, 2021, p. vdab102, https://doi.org/10.1093/noajnl/vdab102.